June 19, 2015

The move gives Teva standing in Dutch court, should they decide to pursue action against Mylan.

June 18, 2015

Teva and Microchips Biotech have announced a partnership that would test Microchips implantable drug delivery device with Teva’s portfolio.

June 16, 2015

Mylan’s largest shareholder has promised to back the company’s bid to buy Perrigo, which would help fend off Teva’s $40 billion takeover offer.

June 2, 2015

The latest addition to Teva’s roster of medication is its generic version of Intuniv (guanfacine) extended release tablets, a non-stimulant meant to treat attention deficit hyperactivity disorder.

June 1, 2015

Teva announced Monday that it had launched its generic version of Actonel (risedronate sodium) in 5-, 30- and 35-mg dosage strengths. 

May 29, 2015

Teva on Friday announced that it would be rolling out a generic version of Lomedia 24 Fe birth control bills. 

January 20, 2015

Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.

September 4, 2014

Teva Pharmaceutical on Thursday announced the launch of generic Baraclude (entecavir) tablets in 0.5-mg and 1-mg dosage strengths. The company was the first to file, giving it 180 days of marketing exclusivity for the drug. 

September 3, 2014

Teva Pharmaceutical on Wednesday announced that a positive judgment has been given by the U.K. High Court in support of Teva's case against AstraZeneca relating to the validity of EP 1,085,877 covering the SMART (Single inhaler Maintenance And Reliever Therapy) indication for AstraZeneca's fixed dose formoterol/budesonide combination product, Symbicort.

June 20, 2014

Teva has reached a settlement with Perrigo Pharmaceutical and Catalent Pharma Solutions with respect to four patents for Teva’s ProAir HFA (albuterol sulfate) Inhalation aerosol product.

June 17, 2014

Teva has reached settlements with Sandoz, Actavis, Lupin and Apotex with respect to a patent for Teva’s wakefulness product, Nuvigil (armodafinil) tablets.

June 9, 2014

Teva on Monday announced that the Food and Drug Administration approved an expanded label for Azilect (rasagiline tablets) from monotherapy and adjunct to levodopa to now include dopamine agonists.

May 13, 2014

Teva Pharmaeceuticals on Tuesday announced that the Food and Drug Administration accepted the company's supplemental new drug application for a lower dose QNASL (beclomethasone dipropionate) nasal aerosol, which is used for the treatment of seasonal and perennial allergic rhinitis in children ages 4 years to 11 years.

April 21, 2014

Mylan on Friday announced that Supreme Court Chief Justice John Roberts has denied Teva's application for an injunction seeking to prevent Mylan's launch of a generic version of Copaxone (glatiramer acetate injection) pending the Supreme Court's decision on Teva's appeal.

March 25, 2014

Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution.

January 29, 2014

Teva announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL form.

December 26, 2013

Sales of OTC female contraceptives ought to be significant in the coming year.

December 26, 2013

Actavis last year gained approval for its Next Choice, a generic version of Teva Women’s Health’s Plan B One-Step, that now sits on top in emergency contraceptive sales.

December 18, 2013

A new study has found a significant increase in the number of high school students who report having abused a common prescription drug for attention deficit hyperactivity disorder, even as abuse of other prescription drugs has decreased or remained low.

December 17, 2013

Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

November 21, 2013

Teva has introduced a generic version of a drug used to treat attention deficit hyperactivity disorder, the company said Thursday.

November 20, 2013

Use of injectable drugs for multiple sclerosis declined during the 12-month period that ended on June 30 as orally administered drugs for the condition became more popular, according to a new report.

August 7, 2013

Teva Women’s Health, the U.S subsidiary of Teva Pharmaceuticals, announced on Wednesday that the emergency contraceptive Plan B One-Step (levonorgestrel) tablet 1.5 mg is now widely available at retail with no age or point-of-sale restrictions.

May 30, 2013

The Food and Drug Administration last month announced that it has approved an amended application submitted by Teva Women's Health to market Plan B One-Step (levonorgestrel) for use without a prescription by women 15 years of age and older. That approval moved Plan B One-Step from behind the pharmacy counter into the family planning section of the pharmacy.